Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 4Lymphoma, Large-Cell, Anaplastic 3Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Cyclophosphamide 13Bevacizumab 9Interleukin-2 8aldesleukin 7Paclitaxel 7fludarabine phosphate 6fludarabine 6Radiotherapy 6Bortezomib 6Thalidomide 5Gemcitabine 5Filgrastim 5veliparib 4sargramostim 4Vincristine 4Trastuzumab 4Prednisone 4Leucovorin 4Doxorubicin 4Biopsy 4vandetanib 3tariquidar 3romidepsin 3pazopanib 3montanide ISA 51 3Topotecan 3Specimen Handling 3Sorafenib 3Sirolimus 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms × Brentuximab Vedotin × Clear all
NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡